EagleClaw Capital Managment LLC Sells 2,809 Shares of AbbVie Inc. $ABBV

EagleClaw Capital Managment LLC cut its position in AbbVie Inc. (NYSE:ABBV) by 3.9% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 68,965 shares of the company’s stock after selling 2,809 shares during the quarter. AbbVie accounts for approximately 2.4% of EagleClaw Capital Managment LLC’s investment portfolio, making the stock its 7th biggest holding. EagleClaw Capital Managment LLC’s holdings in AbbVie were worth $18,041,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Fisher Asset Management LLC increased its position in shares of AbbVie by 252.6% during the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock valued at $8,760,498,000 after acquiring an additional 23,991,451 shares in the last quarter. Corient Private Wealth LP purchased a new position in AbbVie in the 2nd quarter worth approximately $559,736,000. Legal & General Group Plc bought a new position in AbbVie in the 2nd quarter valued at approximately $2,905,952,000. Jupiter Topco LLC bought a new position in AbbVie in the 2nd quarter valued at approximately $1,560,354,000. Finally, Canada Pension Plan Investment Board purchased a new stake in AbbVie during the 2nd quarter valued at $817,473,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

More AbbVie News

Here’s some of the latest news about ABBV:

• Positive Sentiment: AbbVie reported positive Phase 3 results for QULIPTA in a migraine trial, a potential boost to its neuroscience portfolio and the drug’s growth prospects. AbbVie Reports Positive Phase 3 QULIPTA Migraine Trial Results
• Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

Insider Buying and Selling at AbbVie

In other news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at $24,419,005.60. The trade was a 32.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is owned by corporate insiders.

AbbVie Stock Performance

AbbVie stock opened at $295.18 on Friday. AbbVie Inc. has a one year low of $190.75 and a one year high of $302.93. The stock has a fifty day moving average of $275.51 and a 200 day moving average of $240.91. The stock has a market cap of $521.76 billion, a PE ratio of 50.81, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.09. The firm had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.86 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 13.98 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio is 125.30%.

Analysts Set New Price Targets

A number of analysts have commented on ABBV shares. Argus lifted their target price on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Scotiabank upped their price target on AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. JPMorgan Chase & Co. increased their price objective on AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $275.00 price objective on shares of AbbVie in a report on Monday, November 2nd. Finally, BNP Paribas Exane boosted their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $297.46.

About AbbVie

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.